Clopidogrel
Product Images NDC 71717-101

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 71717-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Megalith Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

64a55883 Ada5 4769 E053 2a91aa0ae5f6

CLOPIDOGREL round light brown tablet shown from both sides, one side plain and the other side embossed with the number '101'. No other markings or packaging details visible. Product labeler is Megalith Pharmaceuticals Inc.*

FDA Label Image

Image Description (Clopidogrel 01)

Chemical structure diagram of clopidogrel sulfate showing its molecular framework including a thiophene ring, a piperidine ring, and a benzene ring with a chlorine atom, along with the sulfate anion (H2SO4).*

FDA Label Image

Image Description (Clopidogrel 02)

A horizontal error bar chart depicting the effect of co-administered proton pump inhibitors (PPI) on active metabolite area under the curve (AUC) for clopidogrel. The chart lists dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg on the vertical axis, with mean values and 90% confidence intervals plotted horizontally from 0.4 to 1.4 on the AUC scale.*

FDA Label Image

Image Description (Clopidogrel 03)

A line graph comparing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up between placebo (+ aspirin) and clopidogrel (+ aspirin) groups. The clopidogrel group shows lower cumulative event rates than placebo, with a stated significance of P=0.00009.*

FDA Label Image

Image Description (Clopidogrel 04)

A forest plot figure titled 'Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study.' The plot displays hazard ratios with 95% confidence intervals for various patient subgroups comparing Clopidogrel to placebo. Subgroups include age, gender, race, cardiac enzyme levels, diabetes, previous myocardial infarction and stroke, heparin/LMWH use, aspirin dosage, GPIIb/IIIa antagonist use, beta-blocker, and ACE inhibitor use. The plot visually shows whether each subgroup favors Clopidogrel or placebo based on hazard ratios represented by squares and horizontal lines on a logarithmic scale.*

FDA Label Image

Image Description (Clopidogrel 05)

A Kaplan-Meier survival curve showing the percentage of patients who died before first discharge over up to 28 days since randomization. The graph compares two groups: placebo with 8.1% deaths (1845 deaths) and Clopidogrel with 7.5% deaths (1726 deaths), indicating a 7% proportional risk reduction in the Clopidogrel group (p = 0.03).*

FDA Label Image

Image Description (Clopidogrel 06)

A Kaplan-Meier survival curve depicting the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days after randomization. The graph compares outcomes between placebo and Clopidogrel groups, showing a lower event rate for Clopidogrel with a 9% proportional risk reduction noted.*

FDA Label Image

Image Description (Clopidogrel 07)

A forest plot chart comparing clinical outcomes between Clopidogrel and placebo across subgroups defined by gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The chart shows odds ratios with 95% confidence intervals, indicating the favorability towards Clopidogrel or placebo.*

FDA Label Image

Image Description (Clopidogrel 08)

A line graph showing cumulative event rate (%) on the y-axis versus months of follow-up on the x-axis (0 to 36 months). It compares fatal or non-fatal vascular event rates between Clopidogrel and Aspirin groups, with Clopidogrel showing a slightly lower event rate than Aspirin over time. The graph includes a p-value of 0.045 indicating statistical comparison.*

FDA Label Image

Image Description (Clopidogrel 09)

A forest plot chart comparing hazard ratios for Clopidogrel versus Aspirin across qualifying conditions: Stroke, MI, PAD, and Overall. The chart shows numerical data for number of patients (N), event counts and percentages for Clopidogrel and Aspirin groups, and a graphical representation with squares and confidence intervals indicating favorability between treatments.*

FDA Label Image

Image Description (Clopidogrel Bottle Label 03)

Clopidogrel Tablets, USP 75 mg label from Megalith Pharmaceuticals Inc, containing 30 tablets. The label includes storage instructions, manufacturing details by CSPC Ouji Pharmaceutical Co., and states the product is Rx only. It also notes the tablet contains 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base, with directions to see the package insert for adult dosage.*

FDA Label Image

Image Description (Clopidogrel Bottle Label 09)

Clopidogrel Tablets USP 75 mg label from Megalith Pharmaceuticals Inc. The label indicates a package of 90 tablets with the NDC 71717-101-09. It includes storage instructions, manufacturer (CSPC Ouyi Pharmaceutical, China), and distributor information (Megalith Pharmaceuticals, Princeton, NJ). Each tablet contains 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base. The label notes usual adult dosage guidance and medication guide dispensing instructions.*

FDA Label Image

Image Description (Clopidogrel Bottle Label 50)

Label for Clopidogrel Tablets, USP 75 mg by Megalith Pharmaceuticals Inc. The bottle contains 500 tablets with each tablet providing 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base. Storage instructions and distributor information are also present on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.